933.gm1VrBAF9H634Dbyu1M2BRfS0taUkkHZ3m2CS2717LA.1wQx6WJQmzfxuFidj2VRc3G06pnk8QOX6CLxASeB3_P3Wy3gQ02CHYGsew
13/11 BofA Securities Adjusts Price Target on Perspective Therapeutics to $1 From $5 MT
10/11 Wedbush Adjusts Price Target on Perspective Therapeutics to $7 From $9, Maintains Outperform Rating MT
10/11 Perspective Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
06/11 Perspective Therapeutics, Inc. Presents Updated Interim Results From Phase 1/2a Clinical Trial Of [212Pb]Lapemelanotide Zapixetar For Unresectable Or Metastatic Melanoma CI
06/11 Perspective Therapeutics Presents Incremental Data And Analyses From Phase 1/2a Trial Of [212Pb] Bamzireotide Navoxetan (VMT-a-NET) In Advanced SSTR2 Expressing NETs CI
26/10 Perspective Therapeutics Facing Execution Risks in Bamzireotide Navoxetan's Development, RBC Says MT
26/10 RBC Downgrades Perspective Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $14, Keeps Speculative Risk MT
26/10 Wedbush Adjusts Price Target on Perspective Therapeutics to $9 From $11, Keeps Outperform Rating MT
24/10 Perspective Therapeutics, Inc. Announces New Interim Results From Ongoing Phase 1/2a Clinical Trial Of [212Pb]VMT-a-NET In Advanced SSTR2-Expressing NETs CI
23/10 Perspective Reports 'Encouraging' Bamzireotide Profile in Tumor Trial MT
08/10 Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors CI
08/10 Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium AQ
08/10 Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell MT
08/10 Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors AQ
07/10 Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium AQ
02/10 Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 AQ
21/09 Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index CI
18/09 William Blair Initiates Perspective Therapeutics With Outperform Rating MT
14/09 Perspective Therapeutics, Inc. and Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors CI
14/09 Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell MT
14/09 Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors AQ
11/09 Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 AQ
19/08 BMO Capital Initiates Perspective Therapeutics at Outperform MT
14/08 BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 MT
11/08 Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says MT

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.